The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).

A woman with advanced dementia appeared to regain speech and independence after psilocybin. The findings are intriguing, but far from proof.

Alzheimer's-Related Psychosis: Interdisciplinary Perspectives for Understanding and Responding to Delusions and Hallucinations"—the latest report in The Gerontological Society of America's Insights & ...

(RTTNews) - MapLight Therapeutics, Inc. (MPLT) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to ML-007C-MA for the treatment of hallucinations and delusions ...

Researchers at the Champalimaud Foundation in Lisbon have for the first time managed to identify with an imaging technique whether nervous impulses in the brain of rats are flowing in a "bottom-up" ...